Vasculitis associated with immune checkpoint inhibitors—a systematic review
- 1.4k Downloads
Recent experimental and genetic studies have implicated the role of programmed cell death protein 1 (PD-1), programmed cell death protein-ligand 1 (PDL-1), and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) in the pathogenesis of medium and large vessel vasculitis. This study sought to evaluate the occurrence and nature of vasculitis associated with cancer treatment using immune checkpoint inhibition (anti-PD-1, anti-PDL-1, and anti-CTLA4). A systematic review of the medical literature was conducted by searching all available clinical data up to February 2018 in several databases and search engines including Cochrane Library, Embase, Google Scholar, Medline, Scopus, Web of Science, and Clinicaltrials.gov. Searches included the following FDA-approved anti-PD1 (nivolumab and pembrolizumab), anti-PDL1 (atezolizumab, avelumab, and durvalumab), and anti-CTLA4 (ipilimumab). The vasculitis cases were compiled and classified based on the 2012 revised Chapel Hill Consensus Conference nomenclature. The clinical feature of the vasculitis cases and their relationship to immune checkpoint inhibition was assessed. There were 53 cases of vasculitis of which 20 were confirmed. The main reported type of vasculitis was large vessel vasculitis and vasculitis of the central and peripheral nervous system. All cases resolved with either holding the immune checkpoint inhibitors and/or administering glucocorticoids. No death related to vasculitis was reported. Vasculitis, namely large vessel and vasculitis of the nervous system, is associated with immune checkpoint inhibition. Results of this study add to the growing evidence regarding the relationship between immune checkpoints and vasculitis and suggest that the pathway may be a therapeutic target.
KeywordsCTLA-4 Immune checkpoint inhibitors PD-1 PDL-1 Vasculitis
Compliance with ethical standards
The manuscript does not contain clinical studies or patient data information.
- 12.Pinkston O FB, Wang B (2016) Type and frequency of immune-related adverse reactions in patients treated with pembrolizumab (keytruda), a monoclonal antibody directed against PD-1, in advanced melanoma at a single institutionGoogle Scholar
- 13.Liao B, Wang W, Hammack J, Mauermann M (2016) Vasculitic neuropathy in the setting of nivolumab therapy for metastatic mesothelioma. Ann Neurol 80:M279Google Scholar
- 19.Roy AK, Tathireddy HR, Roy M (2017) Aftermath of induced inflammation: acute periaortitis due to nivolumab therapy. BMJ Case Rep:2017Google Scholar
- 23.Le Burel S, Champiat S, Mateus C, Marabelle A, Michot JM, Robert C et al (2017) Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1/anti-programmed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis. Eur J Cancer 82:34–44CrossRefPubMedGoogle Scholar
- 24.Ban BH CJ, Graham RM (2017) Rheumatology case report immune-related aortitis associated with ipilimumab. The Rheumatologist 2017Google Scholar
- 27.Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CGM, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DGI, Specks U, Stone JH, Takahashi K, Watts RA (2013) 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum 65:1–11CrossRefPubMedGoogle Scholar